Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | GRK6 | P43250 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582873 | 0.83 | AKR1B1 (0.50) | KMT2AMEN1MAPTMAPK1GAA | |
| SCHEMBL20202988 | 0.83 | PKM (0.48) | KMT2AKAT2BIDO1MAPTHTT | |
| SCHEMBL17481368 | 0.78 | CTSB (0.40) | KMT2AMEN1TSHRCYP3A4IDO1 | |
| SCHEMBL17586644 | 0.75 | EDNRA (0.42) | CYP3A4MAPTTDP1MAPK1L3MBTL1 | |
| SCHEMBL16062179 | 0.73 | FGFR4 (0.41) | TSHRCYP3A4MAPTHTTTDP1 | |
| SCHEMBL978709 | 0.72 | TSHR (0.62) | KMT2ATSHRCYP3A4KAT2BGRK6 | |
| SCHEMBL2330493 | 0.72 | L3MBTL1 (0.65) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL2974822 | 0.71 | CYP3A4 (0.60) | TSHRCYP3A4KAT2BGRK6MAPT | |
| SCHEMBL12786875 | 0.71 | FBP1 (0.59) | KMT2AMEN1TSHRCYP3A4KAT2B | |
| SCHEMBL1812600 | 0.71 | TSHR (0.60) | KMT2AMEN1TSHRCYP3A4KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2018-05-31 | — | — | US | disclosed |
| US-9914708-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9481653-B2 | Benzoimidazol-1,2-yl amides as Kv7 channel activators | KNOPP BIOSCIENCES LLC (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KMT2A 507/4885MEN1 2929/4885TSHR 3699/4885 |
| US-20180148419-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KMT2A 507/4885MEN1 2929/4885TSHR 3699/4885 |
| US-20160075663-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | KMT2A 507/4885MEN1 2929/4885TSHR 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.